|
CDK17 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.718200E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.009600E-01 |
| Normal-vs-Stage2 |
2.699000E-01 |
| Normal-vs-Stage3 |
2.106000E-01 |
| Normal-vs-Stage4 |
3.187800E-02 |
| Stage1-vs-Stage2 |
2.714200E-01 |
| Stage1-vs-Stage3 |
1.350620E-01 |
| Stage1-vs-Stage4 |
2.107600E-02 |
| Stage2-vs-Stage3 |
9.813800E-01 |
| Stage2-vs-Stage4 |
3.338200E-01 |
| Stage3-vs-Stage4 |
3.077600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.089000E-01 |
| Normal-vs-AfricanAmerican |
9.132400E-01 |
| Normal-vs-Asian |
8.251400E-01 |
| Caucasian-vs-AfricanAmerican |
4.800200E-01 |
| Caucasian-vs-Asian |
6.037000E-01 |
| AfricanAmerican-vs-Asian |
7.710600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.543800E-01 |
| Normal-vs-Female |
3.006000E-01 |
| Male-vs-Female |
4.951800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.926400E-01 |
| Normal-vs-Age(41-60Yrs) |
1.915210E-01 |
| Normal-vs-Age(61-80Yrs) |
4.922300E-02 |
| Normal-vs-Age(81-100Yrs) |
8.105200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.599600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.155100E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.174000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.451000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.298400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.756000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.648300E-02 |
| Classical-VS-Follicular |
7.013100E-04 |
| Classical-VS-Other |
3.810200E-01 |
| Classical-VS-Normal |
8.762400E-01 |
| Tall-VS-Follicular |
7.880400E-01 |
| Tall-VS-Other |
9.160200E-01 |
| Tall-VS-Normal |
1.257410E-01 |
| Follicular-VS-Other |
8.020800E-01 |
| Follicular-VS-Normal |
2.586000E-02 |
| Other-VS-Normal |
4.396400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.387800E-02 |
| Normal-vs-N1 |
3.659600E-01 |
| N0-vs-N1 |
5.452800E-01 |
|
|
